RxDoctor Payments Data

Edmond Lee

Podiatrist · Monterey Park, CANPI 1174552541

Payments from drug & device makers

$572in general payments, 2019–2025

Across 20 payments — averaging $28.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cardiovascular Systems Inc.$146
  • Smith+Nephew$139
  • Avanos Medical$114
  • Ortho Dermatologics, A Division Of Bausch Health US, LLC$48
  • Nabriva Therapeutics, PLC$37
  • Amgen$37
  • plus $50 from 3 others

What the payments were for

  • Food & beverage$572100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$572 in reported general payments places this provider in the 45th percentile of 721 podiatrist providers in California.

See all podiatrist providers in California

Medicare billing

Part B allowed, 2024
$332,364
Medicare patients
667
Services billed
5,868

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CiclopiroxCiclopirox Olamine1,112$23,171
SantylCollagenase Clostridium Hist.16$8,832
Clotrimazole121$4,044
Diclofenac Sodium71$3,571
Ammonium Lactate125$2,409
Ciclopirox45$1,376
Gentamicin Sulfate20$1,023
Econazole Nitrate17$881
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip49$854
Mupirocin162$835
Fluocinonide27$716
Cephalexin74$454
Gabapentin82$288
Triamcinolone Acetonide33$267
Allopurinol46$243

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$139$8,83216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 721 podiatrist providers in California.

Other podiatrist in Monterey Park

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →